159 related articles for article (PubMed ID: 19775647)
1. PSA screening--a review of recent studies.
Schröder FH
Eur J Cancer; 2009 Sep; 45 Suppl 1():402-4. PubMed ID: 19775647
[No Abstract] [Full Text] [Related]
2. Informed consent for PSA testing.
Brown V
J Fam Pract; 1996 Sep; 43(3):234-5. PubMed ID: 8797747
[No Abstract] [Full Text] [Related]
3. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen and screening for prostate cancer.
Han M; Gann PH; Catalona WJ
Med Clin North Am; 2004 Mar; 88(2):245-65, ix. PubMed ID: 15049577
[TBL] [Abstract][Full Text] [Related]
5. How to use PSA to screen for prostate cancer.
Little B; Young M
Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
[TBL] [Abstract][Full Text] [Related]
6. [Screening for prostate cancer--what does the evidence show?].
Borre M; Iversen P
Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: current recommendations.
Wilson SS; Crawford ED
Urol Clin North Am; 2004 May; 31(2):219-26. PubMed ID: 15123402
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
Gosselaar C; Roobol MJ; Schröder FH
BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
Mian BM
Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
[No Abstract] [Full Text] [Related]
10. Screening for prostate cancer.
Ruffin MT
J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
[No Abstract] [Full Text] [Related]
11. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
12. ERSPC and PLCO prostate cancer screening studies: what are the differences?
Schröder FH; Roobol MJ
Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
[No Abstract] [Full Text] [Related]
13. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
Loeb S; Carter HB
Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
[No Abstract] [Full Text] [Related]
14. PSA screening.
Cohen S; Schiff S; Kelty P
Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782
[No Abstract] [Full Text] [Related]
15. [Prostatic specific antigen in practice in 1997].
Salomon L; Colombel M; Patard JJ; Chopin D; Abbou CC
Ann Urol (Paris); 1998; 32(2):69-72. PubMed ID: 9599634
[TBL] [Abstract][Full Text] [Related]
16. PSA and prostate cancer screening: the challenge of the new millennium.
Bjartell A
Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
[No Abstract] [Full Text] [Related]
17. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
Hoffman RM; Adams-Cameron ML; Murata GH
J Clin Epidemiol; 2004 Oct; 57(10):1071-5. PubMed ID: 15528058
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
19. Detection characteristics in randomized prostate screening.
Schröder FH; Roobol MJ
Clin Cancer Res; 2004 Sep; 10(17):5641-2. PubMed ID: 15355886
[No Abstract] [Full Text] [Related]
20. [Early detection of cancer of the prostate. Pros and cons].
Hoesl CE; Altwein JE
MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
